Acrivon Therapeutics, Inc. specializes in developing drugs to treat cancer. The company has one candidate drug, ACR-368, in phase one of clinical trials as a combination therapy and in phase two as a monotherapy for several types of cancer.

ACR-368 is a selective low-molecular-weight inhibitor currently being tested to treat difficult-to-treat cases of endometrial, bladder, and ovarian cancer that are resistant to other therapies.

The company's main development is the Acrivon Predictive Precision Proteomics (AP3) research platform, designed to identify targeted drugs against cancer. Such drugs have already been created by other companies, but they are usually highly specialized and effective for only about 10% of cases with clearly defined mutations. The AP3 platform allows for the quick selection of the most effective targeted therapy for specific patients.

Acrivon's related development is the ACR-368 OncoSignature test for cancer diagnosis. It has not yet been approved, but it has successfully passed trials conducted by the American National Cancer Institute and Eli Lilly.
________________________

Number of employees:

25-50
________________________

Headquarters location:

Watertown, Massachusetts, USA